Japan's Perspective on Facilitating Drug Development Through Asian Cooperation in Multi-Regional Clinical Trials: Insights From Regulatory Research

日本对通过亚洲多区域临床试验合作促进药物研发的看法:来自监管研究的启示

阅读:2

Abstract

Multi-regional clinical trials (MRCTs) have recently become a popular strategy for novel drug development, contributing to the early access to novel medicines in participating regions by enhancing development efficiency. To further facilitate MRCTs in Asia, the Japanese government has financially supported research activities in Japan for over 15 years that have studied the effect of ethnic factors on drug responses and identified practical challenges in conducting MRCTs in Asia. This mini-review highlights these research outcomes and related articles and presents our perspective on the current situation and future direction of MRCTs to explore opportunities for more collaboration between Japan and other East Asian/South-East Asian countries to facilitate drug development.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。